Introduction: Inactivating mutations of the SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4) gene and/or loss of the BRG1 (brahma-related gene 1) protein defines SMARCA4-deficient thoracic sarcoma (SMARCA4-dTS), an aggressive neoplasm with a usually fatal outcome. Similar SMARCA4 mutations/BRG1 loss is also seen in a subset of non-small cell lung carcinomas (NSCLCs; SMARCA4-dNSCLCs) that lack alterations in currently targetable oncogenic drivers, that is, EGFR, ALK, and ROS1. There is limited knowledge on the cytomorphological features of these SMARCA4-deficient thoracic neoplasms. Methods: We retrospectively analysed the cytology of 2 cases each of SMARCA4-dNSCLC and SMARCA4-dTS to understand their cytomorphological overlap, if any, and identify features that would prompt testing for BRG1 loss. Results: All 4 patients were males presenting with advanced disease, with a mean age of 41.5 years (SMARCA4-dTS) and 58.5 years (SMARCA4-dNSCLC) at presentation. The cytology of the 2 SMARCA4-dTSs was strikingly similar, showing predominantly singly dispersed rhabdoid phenotype tumour cells with perinuclear cytoplasmic condensations in an inflammatory or necrotic background. The cytology raised suspicion for a wide range of differentials, including melanoma, high-grade lymphoma, germ cell tumour, undifferentiated carcinoma, and undifferentiated sarcoma. SMARCA4-dNSCLCs, on the other hand, were recognizable as poorly differentiated (adeno)carcinomas and were easily distinguished from SMARCA4-dTSs, with both cases showing cohesive clusters of frequently large tumour cells with abundant pale cytoplasm. Conclusion: A diagnosis of SMARCA4-dTS is possible on cytology with appropriate ancillary testing and a high index of suspicion. The cytology of SMARCA4-dNSCLCs does not overlap with SMARCA4-dTS; rather, it resembles that of any poorly differentiated (adeno)carcinoma in the limited numbers analysed in this study.

1.
Le Loarer
F
,
Watson
S
,
Pierron
G
,
de Montpreville
VT
,
Ballet
S
,
Firmin
N
, et al
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
.
Nat Genet
.
2015
;
47
(
10
):
1200
5
.
2.
Sauter
JL
,
Graham
RP
,
Larsen
BT
,
Jenkins
SM
,
Roden
AC
,
Boland
JM
, et al
SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior
.
Mod Pathol
.
2017
;
30
(
10
):
1422
32
.
3.
Perret
R
,
Chalabreysse
L
,
Watson
S
,
Serre
I
,
Garcia
S
,
Forest
F
, et al
SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses
.
Am J Surg Pathol
.
2019
;
43
(
4
):
455
65
.
4.
Nambirajan
A
,
Parshad
R
,
Goyal
A
,
Mithun
NK
,
Jain
D
.
Innocuous clinical presentation of a SMARCA4-deficient thoracic sarcoma arising in a patient with chronic empyema thoracis
.
Pathology
.
2019
;
51
(
6
):
657
9
.
5.
Yoshida
A
,
Kobayashi
E
,
Kubo
T
,
Kodaira
M
,
Motoi
T
,
Motoi
N
, et al
Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
.
Mod Pathol
.
2017
;
30
(
6
):
797
809
.
6.
Rekhtman
N
,
Montecalvo
J
,
Chang
JC
,
Alex
D
,
Ptashkin
RN
,
Ai
N
, et al
Thoracic SMARCA4-deficient sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
.
J Thorac Oncol
.
2020
;
15
(
2
):
231
47
.
7.
Nambirajan
A
,
Singh
V
,
Bhardwaj
N
,
Mittal
S
,
Kumar
S
,
Jain
D
.
SMARCA4/BRG1-Deficient non-small cell lung carcinomas: a case series and review of the literature
.
Arch Pathol Lab Med
.
2020
.
Epub ahead of print
.
8.
Morel
D
,
Almouzni
G
,
Soria
JC
,
Postel-Vinay
S
.
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
.
Ann Oncol
.
2017
;
28
(
2
):
254
69
.
9.
Agaimy
A
,
Fuchs
F
,
Moskalev
EA
,
Sirbu
H
,
Hartmann
A
,
Haller
F
.
SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg/CK7pos/HepPar-1pos immunophenotype
.
Virchows Arch
.
2017
;
471
(
5
):
599
609
.
10.
Matsushita
M
,
Kuwamoto
S
.
Cytologic features of SMARCA4-deficient thoracic sarcoma: a case report and comparison with other SWI/SNF complex-deficient tumors
.
Acta Cytol
.
2018
;
62
(
5–6
):
456
62
.
11.
Takeda
M
,
Tani
Y
,
Saijo
N
,
Shimizu
S
,
Taniguchi
Y
,
Otsuka
K
, et al
Cytopathological features of SMARCA4-deficient thoracic sarcoma: report of 2 cases and review of the literature
.
Int J Surg Pathol
.
2020
;
28
(
1
):
109
14
.
12.
Nambirajan
A
,
Kaur
H
,
Jangra
K
,
Kaur
K
,
Madan
K
,
Mathur
SR
, et al
Adenocarcinoma predominant pattern subtyping and nuclear grading in cytology: is there a role in prognostication of advanced pulmonary adenocarcinomas?
Cytopathology
.
2018
;
29
(
2
):
163
71
.
13.
Takada
K
,
Sugita
S
,
Murase
K
,
Kikuchi
T
,
Oomori
G
,
Ito
R
, et al
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report
.
Thorac Cancer
.
2019
;
10
(
12
):
2312
5
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.